Mayo Collaboration Finds Source Of Breast Drug Side Effect
"Many women stop taking aromatase inhibitors due to the accompanying joint pain," says James Ingle, M.D., Mayo Clinic oncologist and senior author of the study. "We used the latest genetic technology in a very large group of women and discovered totally new clues to the cause of the main reason women stop this potentially lifesaving drug. Our findings open the door to finding ways to identify women who will develop these side effects and treat those who do, thus allowing more women to take this therapy and decrease their chances of breast cancer recurrence." Aromatase inhibitors are most often used as adjuvant therapy for postmenopausal women with early stage breast cancer.
How the Research Was Conducted
The researchers -- including investigators from the United States, Canada and Japan -- conducted a genome-wide association study to identify gene variants called single nucleotide polymorphisms (SNPs) that are associated with musculoskeletal pain. They selected patients who were enrolled in a prospective clinical trial, MA27, conducted by the NCIC Clinical Trials Group in Canada in collaboration with the NCI-sponsored North American Breast Cancer Groups comparing two aromatase inhibitor drugs. Two controls were matched with each patient and each patient who was selected experienced arthritis-like side effects within the first two years of treatment, or had already dropped out of the trial because of the pain. Researchers studied 293 separate cases, comparing them to 585 controls.
They found four likely SNPs on chromosome 14, all of which were nearest the gene T-Cell Leukemia 1A, which they discovered also was estrogen dependent. One of the SNPs also created an estrogen response with increased gene expression after exposure to estradiol, a widely used post-menopausal treatment. The results provide researchers with genetic markers for the aromatase inhibitor-induced arthritis and clues to find ways to treat it.
Support for the study came from the National Institutes of Health (NIH), the Canadian Cancer Society, the Biobank Japan Project funded by the Ministry of Education, Culture, Sports, Science and Technology, and the Breast Cancer Research Foundation. Other support was provided by the NIH Pharmacogenomics Research Network and the RIKEN Center for Genomic Medicine Global Alliance. The trial mentioned in the study was supported in part by Pfizer, Inc.
Other researchers include Daniel Schaid, Ph.D., Gregory Jenkins, Anthony Batzler, Mohan Liu, Ph.D., Liewei Wang, M.D., Ph.D., Matthew Goetz, M.D., and Richard Weinshilboum, M.D., all of Mayo Clinic; Paul Goss, M.B., BCh, Ph.D. Massachusetts General Hospital Cancer Center, Harvard University; Taisei Mushiroda, Ph.D., Michiaki Kubo, M.D., Ph.D., and Yusuke Nakamura, M.D., Ph.D., RIKEN Center for Genomic Medicine, Tokyo; Judy-Anne Chapman, Ph.D., Lois Shepherd, M.D., and Joseph Pater, M.D., NCIC Clinical Trials Group, Kingston, Ontario; Matthew Ellis, M.B., B.Chir., Ph.D., Washington University, St. Louis; Vered Stearns, M.D., John Hopkins School of Medicine, Baltimore; Daniel Rohrer, M.D., Ohio State University Medical Center, Columbus; Kathleen Pritchard, M.D., Sunnybrook Odette Regional Cancer Centre, University of Toronto; and David Flockhart, M.D., Ph.D., Indiana University, Indianapolis.
Source: Mayo Clinic
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Clinic, Mayo. "Mayo Collaboration Finds Source Of Breast Drug Side Effect." Medical News Today. MediLexicon, Intl., 28 Sep. 2010. Web.
22 Jun. 2017. <http://www.medicalnewstoday.com/releases/202640.php>
Clinic, M. (2010, September 28). "Mayo Collaboration Finds Source Of Breast Drug Side Effect." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.